Plasma PSMA-positive EV concentration was statistically different among patients with BPH, and low-risk, intermediate-risk, and high-risk PCa (21.9, 43.4, 49.2, 59.9 ng/mL, respectively, p < 0.001), whereas plasma CD63-positive EV concentration was not significantly different among patients with different disease status (128, 141, 140, 155 × 106 ng/mL, respectively, p = 0.114; Fig. 5). This evidence concerns the gene CD63 and benign prostatic hyperplasia.